About Ceapro
Ceapro is a company based in Edmonton (Canada) founded in 1997. Ceapro offers products and services including Macimorelin DX, Avenanthramides, Oat Beta Glucan, Pressurized Gas Expanded (PGX), and AIM Biologicals. Ceapro operates in a competitive market with competitors including Avidity Biosciences, Univercells, OmniActive, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter Edmonton, Canada
- Stage Public
-
Sectors
HealthcareAgriculture
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$670.32 K (USD), Grant
Aug 27, 2019
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ceapro
Ceapro offers a comprehensive portfolio of products and services, including Macimorelin DX, Avenanthramides, Oat Beta Glucan, Pressurized Gas Expanded (PGX), and AIM Biologicals.
Diagnostic tool for assessing growth hormone deficiency in patients.
Oat-derived ingredient for potential antioxidant and health benefits.
Fiber-based product supporting immune and cardiovascular health functions.
Expanded gas technology for drug delivery applications in treatments.
Biological agents in development for targeted therapeutic uses.
Experimental agent for potential oncology or endocrine applications.
Variant of macimorelin for growth hormone stimulation testing.
People of Ceapro
Unlock access to complete
Unlock access to complete
Funding Insights of Ceapro
Investors in Ceapro
Ceapro has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Great Canadian Centre for Interest and Research.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Content is created and shared on diverse topics.
|
Locked | Locked | Locked |
Investor details for Ceapro
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ceapro
Investment portfolio details for Ceapro
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ceapro
Detailed financials for Ceapro
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ceapro Comparisons
Peer comparison for Ceapro
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ceapro
Ceapro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, OmniActive, Sutro Biopharma and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Nutritional supplements for multiple health ailments are developed.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Ceapro
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ceapro
Complete news archive for Ceapro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ceapro
Ceapro was founded in 1997 and raised its 1st funding round 8 years after it was founded.
Ceapro is headquartered in Edmonton, Canada. It is registered at Edmonton, Alberta, Canada.
Gilles Gagnon is the current CEO of Ceapro.
Developer of biopharmaceutical products and diagnostic tools. This company develops and commercializes a portfolio of pharmaceutical and diagnostic products, including those addressing unmet medical needs. A key product is an FDA and European Commission-approved oral test for diagnosing adult growth hormone deficiency. The company also develops therapeutic assets and proprietary extraction technology for active ingredients from renewable plant resources, used in cosmeceutical and potential nutraceuticalpharmaceutical applications.
Ceapro's top competitors include Sutro Biopharma, OmniActive and Avidity Biosciences.
Ceapro offers Macimorelin DX, Avenanthramides, Oat Beta Glucan, Pressurized Gas Expanded (PGX), and 3 more products and services.
Ceapro has 1 investor. Key investors include Great Canadian Centre for Interest and Research.